摘要
目的：评价红归胶囊联合化疗治疗肺癌的临床疗效。方法将符合入选标准的肺癌患者61例，采用随机数字表法分为观察组30例和对照组31例，对照组采用化疗，治疗在对照组基础上加服红归胶囊，21 d 为1个疗程，共治疗3个疗程。比较2组治疗后肿瘤客观疗效、生活质量改善情况、中医症状改善情况及毒副反应发生率。结果治疗后，治疗组肿瘤缓解率[26.7%（8/30）比3.2%（1/31），χ2＝4.927]、卡氏评分提高率[23.3%（7/30）比3.3%（1/31），χ2＝5.410]与对照组比较，差异均有统计学意义（P＜0.05）；治疗组显著改善4例（13.3%），对照组未见显著改善患者。2组显著改善率比较，差异有统计学意义（χ2＝4.423、P＝0.035）；治疗期间，治疗组骨髓抑制发生率[33.3%（10/30）比58.1%（18/31），χ2＝4.778]、消化道反应发生率[16.7%（5/30）比58.1%（18/31），χ2＝11.124]与对照组比较，差异均有统计学意义（P＜0.05）。结论红归胶囊配合化疗可改善肺癌患者的临床症状，提高疗效，减轻化疗的毒副作用。
Objective To observe the clinical efficacy of Honggui capsule combined with chemotherapy in the treatment of lung cancer. Methods 61 cases of lung cancer patients were randomly divided into group A of 30 cases, treated with Honggui Capsule and chemotherapy, and group B of 31 cases treated with chemotherapy only by the envelope method. After both groups were treated for 21 days, the clinical effect, life quality improvement, improvement of TCM symptoms and the incidence of toxic and side effects in 2 groups were compared. Results After treatment, there was significant difference between group A and B in the tumor response rate （26.7% vs. 3.2%; χ2=4.927, P=0.026）, Karnofsky （23.3% vs. 3.3%; χ2=5.410, P=0.020）, and improvement of TCM symptoms （13.3% vs. 0.0%; χ2=4.423, P=0.035）. During treatment, there was significant difference between group A and B in bone marrow suppression （33.3% vs. 58.1%; χ2=4.778, P=0.029）, and gastrointestinal disturbance （16.7% vs. 58.1%; χ2=11.124, P=0.001）. Conclusion Honggui capsule combined with chemotherapy has an enhanced efficacy and a detoxicating effect, besides it improves clinical symptoms and reduces the side effects of chemotherapy.
出处
《国际中医中药杂志》
2015年第11期991-993,共3页
International Journal of Traditional Chinese Medicine
基金
牡丹江市科学技术计划项目（Z2014S085）
关键词
肺肿瘤
红归胶囊
抗肿瘤联合化疗方案
生活质量
疗效比较研究
Lung neoplasms
Honggui capsule
Antineoplastic combined chemotherapy protocols
Quality of life
Comparative effectiveness research
